Atopic Dermatitis Eczema clinical trials

Explore recruiting atopic dermatitis eczema clinical trials.

Recruiting atopic dermatitis eczema studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Atopic Dermatitis Eczema trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase IV randomised, double-blind, parallel-design, controlled multi-center trial of a NOVel moisturiser for Atopic dermatitis: effect on relapse prevention in children, NOVA II

Germany, Sweden

Therapeutic use (Phase IV) EU CTIS Study details

J2T-MC-KGBI/DRM06-AD13: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis

Poland, Spain, Czechia, Germany, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

J2T-MC-KGBJ/DRM06-AD16 A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Spain, Poland, France, Germany, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase I/II randomized, assessor-blind, vehicle-controlled study to assess the safety, tolerability, and pharmacodynamics of DLQ03 in a wound healing model in patients with mild to moderate atopic dermatitis that are colonized with S. Aureus

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

Netherlands, Denmark, Hungary, Ireland, Portugal, Italy +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

France, Estonia, Croatia, Finland, Denmark, Bulgaria +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Atopic Dermatitis Eczema trials by city

Atopic Dermatitis Eczema in Toronto Atopic Dermatitis Eczema in Vancouver Atopic Dermatitis Eczema in Montreal Atopic Dermatitis Eczema in Calgary Atopic Dermatitis Eczema in Edmonton Atopic Dermatitis Eczema in Ottawa Atopic Dermatitis Eczema in Winnipeg Atopic Dermatitis Eczema in Quebec City Atopic Dermatitis Eczema in Hamilton Atopic Dermatitis Eczema in Kitchener Atopic Dermatitis Eczema in London Atopic Dermatitis Eczema in Halifax Atopic Dermatitis Eczema in New York Atopic Dermatitis Eczema in Los Angeles Atopic Dermatitis Eczema in Chicago Atopic Dermatitis Eczema in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease